



Bachem and Axon Neurosciences sign contract for finished dosage forms of peptide-protein conjugate

Bubendorf/Basel, Switzerland and Bratislava, Slovakia

April 3, 2013 – Bachem (SIX: BANB) and Axon Neuroscience SE today announced that the two companies have entered into a collaboration under which Bachem manufactures Axon's investigational API and supplies it as a finished dosage form under Bachem's Clinalfa® brand. Axon's innovative product targeting Alzheimer's disease consists of a peptide-protein conjugate and will enter phase I clinical trials in Europe.

Roman Sivak, CEO of Axon Neuroscience, comments: "We have chosen Bachem because of their stellar reputation for quality work and the wide range of services they provide, spanning from peptide API production to conjugates and fill finish activities."

Dr. José de Chastonay, Chief Marketing Officer of Bachem, added: "Bachem is proud to have been selected as the supplier for Axon's innovative Alzheimer product. Manufacturing a peptide-protein conjugate as well as providing finished dosage forms for clinical trials are valuable services we provide and perfectly complementary to our key expertise in peptides."

About Bachem

Bachem is an independent, technology-based, public biochemicals company providing full service to the pharma and biotech industry. Bachem is specialized in the process development and the manufacturing of peptides and complex organic molecules as active pharmaceutical ingredients (APIs), as well as innovative biochemicals for research purposes. With headquarters in Bubendorf, Switzerland, and affiliates in Europe and the US, Bachem works on a global scale and holds a leading position in the field of peptides.

About Axon Neuroscience

Axon is a biotech pharma company dedicated to the development of disease modifying immunotherapy and early clinical diagnostics for Alzheimer's disease.

Contact:

For further questions, please visit our websites or contact the person below.

Bachem Holding AG
Stephan Schindler, CFO
Tel.: +41 61 935 2333
Fax: +41 61 935 2324
ir@bachem.com
www.bachem.com

Axon Neuroscience
Roman Sivak, CEO
Tel.: +421 220 921 620
Fax: +421 220 921 624
office@axon-neuroscience.eu
www.axon-neuroscience.eu